CN115916337B - 卤代烯丙基胺双胺氧化酶抑制剂 - Google Patents

卤代烯丙基胺双胺氧化酶抑制剂 Download PDF

Info

Publication number
CN115916337B
CN115916337B CN202180043741.6A CN202180043741A CN115916337B CN 115916337 B CN115916337 B CN 115916337B CN 202180043741 A CN202180043741 A CN 202180043741A CN 115916337 B CN115916337 B CN 115916337B
Authority
CN
China
Prior art keywords
disease
mao
compound
ssao
vap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180043741.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115916337A (zh
Inventor
艾伦·邓肯·罗伯森
艾莉森·桃乐丝·芬得利
A·布森
克雷格·伊旺·特纳
D·W·汉佩特
强纳森·史都华·甫特
曼达·迪奥达
沃尔夫冈·杰洛利梅克
S·贝奇
B·W·巴伦
M·坎顿
L·维蒂略
B·布拉奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaxis Ltd
Original Assignee
Pharmaxis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902152A external-priority patent/AU2020902152A0/en
Application filed by Pharmaxis Ltd filed Critical Pharmaxis Ltd
Publication of CN115916337A publication Critical patent/CN115916337A/zh
Application granted granted Critical
Publication of CN115916337B publication Critical patent/CN115916337B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/46—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180043741.6A 2020-06-26 2021-06-25 卤代烯丙基胺双胺氧化酶抑制剂 Active CN115916337B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902152A AU2020902152A0 (en) 2020-06-26 Haloallyamine dual amine oxidase inhibitors
AU2020902152 2020-06-26
PCT/AU2021/050675 WO2021258159A1 (en) 2020-06-26 2021-06-25 Haloallylamine dual amine oxidase inhibitors

Publications (2)

Publication Number Publication Date
CN115916337A CN115916337A (zh) 2023-04-04
CN115916337B true CN115916337B (zh) 2025-04-15

Family

ID=79282315

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043741.6A Active CN115916337B (zh) 2020-06-26 2021-06-25 卤代烯丙基胺双胺氧化酶抑制剂

Country Status (5)

Country Link
US (1) US12428370B2 (https=)
EP (1) EP4171740A4 (https=)
JP (1) JP7665122B2 (https=)
CN (1) CN115916337B (https=)
WO (1) WO2021258159A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250022712A (ko) * 2022-05-30 2025-02-17 기초과학연구원 모노아민 산화효소 b에 대한 안티센스 올리고머 및 이의 용도
AU2023331414A1 (en) * 2022-08-29 2025-03-27 Syntara Limited Novel selective inhibitors of lysyl oxidases
KR20250174618A (ko) * 2023-03-22 2025-12-12 쿠보타 비전 인코포레이티드 신경 염증의 치료

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110719902A (zh) * 2017-06-20 2020-01-21 山东丹红制药有限公司 Ssao抑制剂
CN110914234A (zh) * 2017-08-04 2020-03-24 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
AU2013255103B2 (en) * 2012-05-02 2016-09-29 Syntara Limited Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
CN109251166B (zh) * 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
US20210238192A1 (en) * 2018-06-29 2021-08-05 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110719902A (zh) * 2017-06-20 2020-01-21 山东丹红制药有限公司 Ssao抑制剂
CN110914234A (zh) * 2017-08-04 2020-03-24 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用

Also Published As

Publication number Publication date
US20230257342A1 (en) 2023-08-17
JP7665122B2 (ja) 2025-04-21
US12428370B2 (en) 2025-09-30
EP4171740A1 (en) 2023-05-03
EP4171740A4 (en) 2024-01-03
JP2023531468A (ja) 2023-07-24
CN115916337A (zh) 2023-04-04
WO2021258159A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CN115916337B (zh) 卤代烯丙基胺双胺氧化酶抑制剂
US10059669B2 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease
DK3125888T3 (en) 2,4-THIAZOLIDINEDION DERIVATIVES IN THE TREATMENT OF CENTRAL Nervous System Disorders
CN107074836B (zh) 作为bace1抑制剂的2-氨基-6-(二氟甲基)-5,5-二氟-6-苯基-3,4,5,6-四氢吡啶
EP3617186A1 (en) Fluoroallylamine derivative and use thereof
US20170239225A1 (en) Combination therapies for treatment of spinal muscular atrophy
AU2015345259A1 (en) 2-Amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
CN112638866A (zh) 索拉非尼衍生物的共晶体及其制备方法
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
CN118317955A (zh) 作为cd38抑制剂的n-(4-氨基环己基)嘧啶-4-甲酰胺
US20200024285A1 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
CN114728920B (zh) 一种沃替西汀前药及其应用
WO2025107036A1 (en) Dual inhibitors of amine oxidases and peroxidases, and uses thereof
US20080039513A1 (en) Marine Compounds with Calcium Channel Blocking Properties for the Treatment of Cognitive or Neurodegenerative Diseases
Sharma et al. Design, synthesis and biological evaluation of naphthalene-pyrazoline derivatives as neuroprotective agents for alzheimer's disease
WO2025165773A1 (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease
HK40050156B (en) Co-crystal of sorafenib derivatives and process for preparation thereof
HK40050156A (en) Co-crystal of sorafenib derivatives and process for preparation thereof
HK1261676A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1261676B (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233953B (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233953A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233257B (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HK1233257A1 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant